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The use of cetuximab anti-epidermal growth factor
receptor (anti-EGFR) antibodies has opened the era
of targeted and personalized therapy in colorectal
cancer (CRC). Poor response rates have been un-
equivocally shown in mutant KRAS and are even
observed in a majority of wild-type KRAS tumors.
Therefore, patient selection based on mutational
profiling remains problematic. We previously identi-
fiedmethylglyoxal (MGO), a by-product of glycolysis,
as a metabolite promoting tumor growth and metas-
tasis. Mutant KRAS cells under MGO stress show
AKT-dependent survival when compared with wild-
type KRAS isogenic CRC cells. MGO induces AKT
activation through phosphatidylinositol 3-kinase
(PI3K)/mammalian target of rapamycin 2 (mTORC2)
and Hsp27 regulation. Importantly, the sole induction
of MGO stress in sensitive wild-type KRAS cells ren-
ders them resistant to cetuximab. MGO scavengers
inhibit AKT and resensitize KRAS-mutated CRC cells
to cetuximab in vivo. This study establishes a link be-
tween MGO and AKT activation and pinpoints this
oncometabolite as a potential target to tackle
EGFR-targeted therapy resistance in CRC.
INTRODUCTION
Cancer cells undergo an adaptive metabolic shift, known as the
Warburg effect, toward increased use of aerobic glycolysis when
compared with normal cells. In addition to produce ATP, the
glycolytic pathway provides metabolic intermediates needed
for cell growth and proliferation (Vander Heiden and DeBerardi-
nis, 2017). One unavoidable consequence associated with
elevated glycolytic flux is the spontaneous formation of methyl-
glyoxal (MGO) from triose phosphate intermediates (Richard,1400 Cell Reports 30, 1400–1416, February 4, 2020 ª 2020 The Auth
This is an open access article under the CC BY license (http://creative1993). MGO is a highly reactive dicarbonyl compound that gly-
cates proteins, DNA, and lipids much more efficiently than
glucose (Brownlee, 2001; Maessen et al., 2015; Thornalley
et al., 1995).MGOpost-translational modification of arginine res-
idues notably leads to the formation of argpyrimidine and dihy-
droxy-imidazolone (MGO-Hs) protein adducts (Rabbani and
Thornalley, 2012a). Heat shock proteins are direct targets of
MGO glycation, with heat shock protein 27 (Hsp27) being the
best-characterized argpyrimidine detected in several cancer
types, including human colorectal cancer (CRC). MGO-modified
Hsp27 (MGO-Hsp27) is more stable and active than native
Hsp27 and favors cancer cell escape from apoptosis (Oya-Ito
et al., 2006; Sakamoto et al., 2002; van Heijst et al., 2006).
MGO is efficiently detoxified to D-lactate by glyoxalase
1 (GLO1), an ubiquitous cellular enzyme (Rabbani and Thornalley,
2012b). Using a GLO1-silencing strategy, we previously demon-
strated that the direct modification of Hsp90 by MGO favors
YAP nuclear localization and the inactivation of the Hippo tumor
suppressor pathway in breast cancer cells (Nokin et al., 2016).
We showed that MGO stress endowed breast cancer cells with
enhanced growth and metastatic potential, both of which were
efficiently blocked in vivo using MGO scavenger molecules such
as carnosine (beta alanyl-L-histidine) and aminoguanidine (Nokin
et al., 2016, 2019). MGO is cytotoxic and mutagenic, and several
studies demonstrated the pro-apoptotic effect of MGO stress on
cancer cells. In fact, we recently contributed to reveal the dual role
of MGO stress by demonstrating its hormetic effect on cancer
cells, with low concentrations supporting tumor growth and high
levels inducing toxicity and apoptotic death (Nokin et al., 2017).
KRAS mutation represents one of the most prevalent genetic
alterations in cancers. In CRC tumors,85%–90% of KRASmu-
tations occur in exon 2, with codon 12 and 13 being the most
predominant mutations. In particular, KRASG12V mutation is
associated with resistance to apoptosis through AKT activation
(Alamo et al., 2015; Guerrero et al., 2000), higher metastatic po-
tential (Alamo et al., 2015), and mitochondrial dysfunction lead-
ing to glycolytic reprogramming (Hu et al., 2012). Cetuximab
anti-epidermal growth factor receptor (anti-EGFR) therapy isors.
commons.org/licenses/by/4.0/).
A
Figure 1. Evidence of MGO Dicarbonyl Stress in KRAS-Mutated Human CRC Tumors
(A) Detection of MGO adducts as assessed by IHC of argpyrimidines in a series of colon cancer tumors (n = 48). Two representative KRASWT and KRASG12V
mutated CRC tumors are shown. Data are shown as percentage of tumors presenting MGO stress in KRASWT and KRASG12V tumors and were analyzed using a
chi-square contingency test (p = 0.0001). The lower images show the area within the dashed rectangle on the upper images at higher magnification. Scale bars
represent 100 mm. See also Figure S1.aimed at the targeting of the two major pathways activated
through EGFR. The RAS/RAF/MEK/ERK pathway, which
controls gene transcription, cell-cycle progression, and cell
proliferation, and the phosphatidylinositol 3-kinase (PI3K)/AKT
pathway, which activates a cascade of anti-apoptotic and pro-
survival signals. The molecular mechanisms that contribute to
the development of primary and secondary resistance to cetux-
imab in CRC are the subject of intensive clinical and research
studies in order to propose new combined modality approaches
(Bardelli and Siena, 2010; De Roock et al., 2011; Hong et al.,
2016). The detection of KRAS mutation rapidly revealed to be a
strong and useful negative predictive biomarker of CRC
response to cetuximab (Allegra et al., 2016; Lièvre et al., 2006).
Parallel activation of RAS and PI3K pathways (for review, see
Castellano and Downward, 2011) confers maximal resistance to
cetuximab (Jhawer et al., 2008) and points to PI3K/AKT activation
as a crucial player in CRC resistance to targeted EGFR therapy.
Direct interaction of activated KRAS with PI3K subunit p110
(Downward, 2003; Gupta et al., 2007; Rodriguez-Viciana et al.,
1994) has been proposed to explain the constitutive activation
of the PI3K/AKT pathway in a KRAS-mutated setting and its
crucial role in KRAS-mediated transformation. However, it is
noteworthy that in CRC, the knockdown of KRAS in mutant cell
lines did not suppress AKT phosphorylation and led to the discov-
ery of other dominant mechanisms underlying AKT activation in a
KRAS-mutated setting, such as specific tyrosine kinase receptor
signaling (i.e., insulin-like growth factor I receptor) (Ebi et al.,
2011). A better understanding of how AKT signaling is activatedin KRASmutant CRC will point to potential therapeutic strategies
against these tumors refractory to EGFR-targeted therapy.
Our previous demonstration of elevated MGO adducts in hu-
manCRC tumors presenting high FDG-PET (fluorodeoxyglucose
positron emission tomography) metabolic activity (Chiavarina
et al., 2017) and the glycolytic switch shown to occur in KRAS
mutant CRC cells (Hu et al., 2012) prompted us to (1) assess
endogenous MGO stress in KRAS-mutated tumors and cell lines
and (2) envisage the possibility that MGO scavengers could re-
sensitize mutant KRAS tumors to cetuximab.
Using two series of human CRC tumors, we found that thema-
jority of KRASG12V tumors presented high MGO stress and that
this latter correlated with the detection of phosphorylated AKT
(P-AKT). We used SW48 and LIM1215 isogenic human CRC
models, consisting of targeted heterozygous knockin of
KRASG12V, to compare KRAS-mutated cells to their wild-type
counterparts (KRASWT), which do not harbor other frequent
CRC oncogenic mutations (i.e., PTEN, NRAS, BRAF, and
PIK3CA). Such models elude variability of the genetic back-
ground between CRC cell lines that confounds attribution of re-
sults directly to the presence of mutant KRAS. We found
elevated MGO levels and adducts in KRASG12V when compared
with KRASWT cells. Exogenous and endogenous (GLO1
silencing) MGO stress induced a significant activation of AKT,
in wild-type and mutant KRAS, that was abrogated using MGO
scavengers. In vitro, the combination of cetuximab and carno-
sine inhibited KRAS-mutated tumor growth. Importantly, the
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Figure 2. KRASG12V Cells Are More Glycolytic than Isogenic Wild-Type CRC Cells
(A and B) Kinetic measurement of extracellular acidification rate (ECAR) in SW48 CRC cells (A) and LIM1215 CRC cells (B) in response to glucose (20 mM),
oligomycin (oligo, 1 mM), and 2-deoxyglucose (2-DG, 50 mM). Significantly higher glycolytic, maximal, and spare ECAR capacities were observed in KRASG12V
cells when compared with KRASWT cells. Seahorse data were normalized with cell number evaluated using Hoechst incorporation (arbitrary unit [A.U.]). One
representative experiment out of three is shown. Each data point represents mean ± SD, n = 3. ***p < 0.001 and *p < 0.05.
(legend continued on next page)
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CRC cells rendered them resistant. Therefore, MGO stress,
which we prove to be implicated in KRAS-mutated resistance,
should be also taken into account when predicting the efficacy
of EGFR-targeted drugs in a wild-type CRC clinical setting.
RESULTS
Evidence of MGO Dicarbonyl Stress in KRAS-Mutated
CRC Human Tumors and Cell Lines
In glycolytic cells, MGO production and the formation of protein
adducts generate MGO dicarbonyl stress conditions. We previ-
ously demonstrated that elevated MGO adducts are detected in
human CRC malignant lesions when compared with matched
normal colon and are correlated with a pathological stage (Chia-
varina et al., 2017). Using immunohistochemistry (IHC), we spe-
cifically evaluated the levels of MGO adducts in KRASWT and
KRAS-mutated (KRASG12V) CRC tumors (n = 48). MGO adducts
were mainly detectable in the cytoplasm of cancer cells (Fig-
ure 1A). Remarkably, both differentiated and stroma infiltrating
tumor cells displayed detectable MGO adducts in KRASG12V tu-
mors (Figure 1A). The intensity and extent of the immunostaining
were scored, and tumor MGO dicarbonyl stress was evaluated
as high or low, as detailed in STAR Methods. The majority of
KRASG12V tumors displayed high MGO dicarbonyl stress when
compared with KRASWT tumors (chi-square test, p = 0.0001)
(Figure 1A). We observed a similar correlation between KRAS
mutation and MGO stress using a series of 84 rectal human tu-
mors (Fisher’s test, p = 0.03) that we previously characterized
for their KRAS status (Lovinfosse et al., 2016) (Figure S1A).
KRASG12V Cells Are More Glycolytic than Isogenic Wild-
Type CRC Cells
We used SW48 and LIM1215 isogenic CRC models to systemat-
ically characterize the effects of KRAS mutation on cell glycolytic
phenotype. First, the quantitative measurement of the glycolytic
rate of SW48 and LIM1215 cells demonstrated that KRASG12V
cells presented a significantly higher glycolytic capacity upon
glucose challenge thanKRASWT cells (Figures 2A and2B, respec-
tively). Glycolytic, maximal, and spare ECAR (extracellular acidifi-
cation rate) notably indicated that KRASG12V rely more on glycol-
ysis than KRASWT cells in both SW48 and LIM1215 models
(Figures 2A and 2B, respectively). Accordingly, GLUT1 glucose
transporter expression was significantly elevated in KRAS-
mutated cells (Figures 2C and 2D). Second, we evaluated the
expression of key glycolysis cascade enzymes in KRASWT versus
KRASG12V cells. Critical regulatory enzymes in glycolytic control,
including hexokinase II (HK II), PFKB3, the activeM2splice variant
of pyruvate kinase (P-PKM2), and inactive pyruvate dehydroge-
nase (P-PDH) presented with higher basal expression levels in
KRASG12V cells than in KRASWT cells in the SW48 (Figure 2C)
and LIM1215 (Figure 2D) models. Third, 13C-labeled glucose(C and D) GLUT1, HXII, PFKFB3, P-PKM2, PKM2, P-PDH, and PDH levels were a
A representative western blot of at least two independent experiments is shown
(E) Schematic representation of the first steps of glycolysis and MGO production
(F) 13C-glucose metabolic flux analysis performed in SW48 CRC cells using mass
were observed in KRASG12V CRC cells when compared with KRASWT CRC cells
values ± SEM of three independent experiments.flux analysis confirmed enhanced glucose uptake and elevated
amounts of the first intermediates of the glycolysis pathway (Fig-
ure 2E) in SW48KRASG12V cells (Figure 2F). Taken together, these
results indicate that KRASG12V cells present a rewired glucose
metabolism promoted by the overexpression of key effectors of
the glycolytic pathway. These data and our previous demonstra-
tion of MGO adducts accumulation in high 18F-FDG-PET CRC
tumors (Chiavarina et al., 2017) urged us to characterize for the
first time MGO stress in the context of mutant KRAS CRC cells.
Glycolytic Mutant KRAS Cells Produce Higher Amounts
of MGO than Isogenic Wild-Type CRC Cells
In good accordance with their glycolytic phenotype, KRASG12V
SW48 and LIM1215 cells showed a higher level of MGO than
KRASWT cells, as measured in their conditioned media using
liquid chromatography-tandem mass spectrometry (LC-MS/
MS) (Figure 3A). Using this technique, we also detected
13C-labeled MGO in CRC cells challenged with 13C-glucose,
thus providing the first evidence of MGO being a glycolysis by-
product detectable in cancer cells and secreted in the medium
(Figure 3B). Higher accumulation of MGO adducts (argpyrimi-
dines and MG-Hs) was detected in KRASG12V SW48 (Figure 3C)
and LIM1215 (Figure 3C) cells when compared with KRASWT
isogenic cells. GLO1 expression (Figure 3E), GLO1 enzymatic
activity (Figure 3F), and D-lactate production (Figure S2A) were
similar in KRASWT and KRASG12V settings. Accordingly, exoge-
nousMGOwas detoxified into D-lactate by GLO1with compara-
ble efficiency independently of KRAS status (Figure S2B).
Altogether, these data indicate that elevated MGO andMGO ad-
ducts levels observed in KRAS-mutated cells are likely related to
their favored usage of glycolysis, since their GLO1 detoxification
capacity is comparable to the one observed in KRASWT cells.
MGO Stress Induces AKT Activation in CRC Cells that Is
Reverted Using MGO Scavengers
The activation of AKT promotes glucose uptake and stimulates
aerobic glycolysis in cancer cells (Elstrom et al., 2004; Rathmell
et al., 2003). We next observed that basal levels of P-AKT and
its downstream targets, P-GSK3beta and P-P70S6K, were
consistently elevated in KRASG12V cells compared with
KRASWT cells (Figure 4A). To check whether this marked differ-
ence in AKT activation could be related to MGO stress condi-
tions, we treated the cells with two potent MGO scavengers.
Both carnosine (Figure 4B) and aminoguanidine (Figure 4C)
significantly decreased P-AKT levels in both KRASWT and
KRASG12V cells, thus confirming the implication, at least
in part, of MGO stress in the regulation of AKT activity. To sup-
port this important observation, we next reasoned that exoge-
nous MGO treatment should induce AKT activation in CRC
cells. In isogenic models (Figure 4D), it is remarkable that
MGO treatment induced a dose-dependent P-AKT activationssessed in SW48 CRC cells (C) and LIM1215 CRC cells (D) using western blot.
. b-Actin was used for normalization.
.
spectrometry. Higher glucose and glycolytic intermediates (numbered as in E)
. Data are expressed as peak area/number of cells. Data are shown as mean





Figure 3. Glycolytic Mutant KRAS Cells Produce Higher Amounts of MGO than Isogenic Wild-Type CRC Cells
(A) MGO quantification in CRC isogenic models using LC-MS/MS analysis on conditioned culture media. Data were analyzed using unpaired Student’s t test and
are shown as mean values ± SEM of three independent experiments.
(B) Detection of 13C-labeled MGO and unlabeled MGO in CRC cells using LC-MS/MS analysis in conditioned media and cell pellets. Plasma EDTA samples were
used as control for MGO detection (control).
(C and D) Western blot detection of MGO adducts (argpyrimidines and MG-Hs) in SW48 cells (C) and LIM1215 CRC cells (D).
(legend continued on next page)
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in KRASWT cells. In KRASG12V cells, the highest doses of MGO
also increased P-AKT level over the high basal levels constantly
detected in these cells. Elevated intracellular MGO levels were
evidenced upon MGO treatment in CRC cells using methyl di-
aminobenzene-BODIPY (MBo), a fluorescent sensor of MGO
(Wang et al., 2013) (Figure S3A). It is noteworthy that MGO
induced significant activation of AKT in a panel of human
CRC cell lines (i.e., HT29, SW480, HCT116, and Lovo) (Fig-
ure 4E) regardless of their mutational profile (Figure 4F), thus
establishing a link between MGO stress and AKT activation.
Consistently, we found that a majority of high-P-AKT CRC
tumors presented with high MGO stress when compared with
low-P-AKT tumors (Fisher’s test, p = 0.03) (Figure 4G). Remark-
ably, the sole induction of an endogenous MGO stress through
the inhibition of GLO1 expression using specific small inter-
fering RNAs (siRNAs) recapitulated AKT activation in the
SW48 isogenic model (Figure 4H). Increased MGO levels
were detected in GLO1 silenced SW48 cells when compared
with control cells using both the MBo fluorescent sensor of
MGO (Figure S3B) and LC-MS/MS (Figure S3C). Sustaining
further the relationship between de novo MGO stress induction
and P-AKT levels is the fact that the co-treatment with MGO
and its scavengers, carnosine (Figure 4I) and aminoguanidine
(Figure 4J), effectively reversed MGO-mediated AKT activation
in CRC cells. The significant decrease of MGO levels was veri-
fied in carnosine- and aminoguanidine-treated SW48 cells
using LC-MS/MS (Figure S3D).
MGO-Mediated Activation of AKT Occurs through PI3K
and mTORC2 in CRC Cells
In order to explore the molecular mechanisms underlying MGO-
mediated AKT phosphorylation, we first checked the possibility
that MGO could regulate PI3K upstream of AKT activation. We
observed that MGO treatment induced the activation of PI3K in
KRASWT CRC cells and KRASG12V LIM1215 cells (Figure 5A).
Next, we focused on the mammalian target of rapamycin 2
(mTORC2), because this complex directly phosphorylates AKT
on Ser473 (Sarbassov et al., 2005). We found that MGO treat-
ment was sufficient to induce the expression of the mTORC2
components Rictor and mTOR in KRASWT CRC cells (Figure 5B).
MGO induction of mTORC2 was not significant in KRASG12V
CRC cells (data not shown), possibly because of their high basal
level of mTORC2 complex when compared with KRASWT cells
that is likely attributable to the direct binding and activation of
mTORC2 by mutated RAS, as reported recently (Kovalski
et al., 2019). Importantly, the use of torin 1 (an mTORC1 and
mTORC2 inhibitor) completely blocked MGO-mediated AKT
activation, while rapamycin (an mTORC1 inhibitor) did not
(Figures 5C and 5D) in KRASWT and KRASG12V settings in
both isogenic models. These data demonstrate that MGO
acts as a potent inducer of AKT activation through the PI3K/
mTORC2 axis.(E) GLO1 protein levels assessed in CRC cells using western blot. b-Actin was use
experiments is shown.
(F) GLO1 maximal activity measured in CRC cells is expressed as A.U. per mg pro
values ± SEM of three independent experiments.
**p < 0.01; *p < 0.05; ns, not significant. See also Figure S2.High MGO-Glycated Hsp27 (MGO-Hsp27) Sustains AKT
Activation in KRASG12V Cells
To explore the molecular mechanism(s) underlying the link evi-
denced betweenMGO stress and AKT activation, we next envis-
aged the possibility that Hsp27 could be implicated, knowing
that (1) MGO -glycated Hsp27 (MGO-Hsp27) in cancer cells sup-
ports their escape from apoptosis (Oya-Ito et al., 2011; Saka-
moto et al., 2002), (2) Hsp27 chaperone activity has been asso-
ciated with the resistance to different cytotoxic agents (Kamada
et al., 2007; Kuramitsu et al., 2012; Mori-Iwamoto et al., 2007),
and (3) Hsp27 has been shown to control apoptosis by regulating
AKT activation (Rane et al., 2003). First, we undertook the
detection of MGO-Hsp27 in SW48 isogenic model. Immunopre-
cipitation (IP) of argpyrimidine MGO adducts in KRASWT and
KRASG12V cells evidenced Hsp27 detection using western
blotting and confirmed the presence of MGO-Hsp27 in these
cells, with significantly elevated amounts in KRASG12V when
compared with KRASWT cells (Figure 5E). Consistently, the
reverse IP experiment using anti-Hsp27 antibody allowed the
detection of an argpyrimidine adduct of the expected molecular
weight (27 kDa) (Figure 5F). Interestingly, the screening of a
series of human CRC cell lines showed that elevated amounts
of MGO-Hsp27 paralleled high P-AKT levels (Figure 5G). At this
point, our observations let us envisage that activation of AKT in
CRC cells is associated with MGO stress and high MGO-
Hsp27 levels. Previous studies demonstrated that MGO-Hsp27
is more prone to form stable and functional oligomers than its
native form (Oya-Ito et al., 2011; Sakamoto et al., 2002). Our
in vitro glycation of recombinant human Hsp27 (rhHsp27) by
MGO (500 mM) notably favored the formation of MGO-Hsp27
dimers that were present endogenously and detectable in
KRASG12V, but not in KRASWT, protein extracts (Figure S4A).
Knowing that Hsp27 plays a role in AKT activation, we aimed
at exploring further the marked difference between KRASG12V
and KRASWT cells in term of MGO-Hsp27 level. We used cyclo-
heximide to block protein synthesis and measure the half-life of
Hsp27 in the SW48 model. In KRASWT cells, total Hsp27 (with
predominantly native Hsp27) decreased rapidly with time (half-
life was reached after 7.3 h) when compared with total Hsp27
level (with predominantly MGO-Hsp27) of KRASG12V cells, which
showed elevated and stable levels, as shown in Figure S4B and
quantified in Figure S4C. The specific detection of MGO-Hsp27
level further completed this observation, as MGO-Hsp27 was
detected in both cell lines all along cycloheximide challenge
(Figure S4B). In KRASWT cells, the decrease of total Hsp27 in
favor of cellular enrichment in stable MGO-Hsp27 was associ-
ated with the specific increase of P-AKT levels (Figure S4B).
The relationship revealed betweenMGO-Hsp27 and AKT activa-
tion was further assessed in experiments where BioPORTER
reagent was used to deliver rhHsp27 or its in vitro glycated
form, MGO-rhHsp27, into cells by endocytosis. We observed a
significant increase of P-AKT upon MGO-rhHsp27 delivery tod for normalization. A representative western blot of at least three independent
teins. Data were analyzed using unpaired Student’s t test and shown as mean
Cell Reports 30, 1400–1416, February 4, 2020 1405
Figure 4. MGO Stress Induces AKT Activation in CRC Cells that Is Reverted Using MGO Scavengers
(A) Basal levels of P-AKT, P-GSK3b, and P-P70S6K in CRC cells.
(B and C) Basal P-AKT level is decreased upon carnosine (100 mM, 24 h) (B) and aminoguanidine (10 mM, 24 h) (C) treatment in CRC cells.
(D) P-AKT level was assessed after 3 h of MGO treatment at the indicated doses in CRC isogenic models.
(E) P-AKT level was assessed after 3 h of MGO treatment at the indicated doses in the indicated human CRC cell lines.
(F) Oncogenic mutations of the CRC cell lines shown in E.
(G) P-AKT IHC staining in low- and high-MGO stress colon tumors as assessed by their argpyrimidine level. Two representative low and high MGO stress CRC
tumors are shown. Data were analyzed using Fisher’s test (p = 0.03). The lower images show the area within the dashed rectangle on the upper images at higher
magnification. Scale bars represent 100 mm.
(legend continued on next page)
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SW48 KRASWT cells (Figure 5H). Next, we used specific siRNAs
directed against Hsp27 in KRASWT and KRASG12V cells treated
with MGO. In the absence of MGO-Hsp27, exogenous MGO
treatment was less efficient at inducing P-AKT (Figure 5I). The ul-
timate demonstration of the role of endogenous MGO-Hsp27 in
AKT activation arose from carnosine (Figure 5J) and aminogua-
nidine (Figure 5K) treatments, which induced a significant
decrease of MGO-Hsp27 in KRASG12V cells that was paralleled
by P-AKT inhibition in CRC cells.
Carnosine Specifically Inhibits KRASG12V Cell
Clonogenic Potential In Vitro and Tumor Growth In Vivo
After having established the potent effect of carnosine as an in-
hibitor of AKT activity in CRC cells. We next aimed at demon-
strating the crucial dependence of KRAS-mutated CRC cells
on AKT for their survival. In fact, significantly lower concentra-
tions of LY294002 and BYL719 (PI3K inhibitors) and MK2206
(AKT inhibitor) were necessary to decrease by half the viability
of KRAS-mutated cells when compared with wild-type cells (Fig-
ure 6A). KRASG12V showed a significant apoptotic death when
challenged with PI3K/AKT inhibition, while KRASWT cells did
not (Figure 6B), thus validating the higher dependency of
KRAS-mutated cells on AKT activation. Efficient inhibition of
AKT phosphorylation in presence of each inhibitor is shown in
Figure S5A.
We next compared the capacity for continued proliferation of
KRASWT and KRASG12V cells in presence of carnosine. Clono-
genic assay performed on SW48model showed a lower capacity
of KRASG12V cells to produce colonies in presence of carnosine
when compared with KRASWT (Figure 6C). Accordingly,
KRASG12V cells proved to be significantly more sensitive to
carnosine treatment in comparison with KRASWT cells (Fig-
ure 6D). Carnosine provoked a 2.3-fold increase of apoptosis
in SW48 KRASG12V as assessed using Annexin V assay (Fig-
ure 6E), while KRASWT did not show any significant apoptosis
change at the same dose. Likewise, aminoguanidine treatment
induced apoptosis only in KRAS-mutated cells (Figure 6E). In
presence of both MGO scavengers (Figure 6F), KRASG12V cells
showed a strong increase of cleaved poly (ADP-ribose) polymer-
ase (PARP) and cleaved caspase 3 apoptosis markers. Evidence
sustaining carnosine pro-apoptotic effect via AKT inhibition was
brought using SC-79, a specific AKT activator. The effect of SC-
79 on carnosine-induced apoptosis was evaluated by pretreat-
ing KRASG12V cells with increasing doses of SC-79 beginning
2 h before the addition of carnosine. The percentage of apoptotic
cells was globally decreased in the presence of SC-79 and
reached significance at the higher dose used (Figure 6G), thus
demonstrating that carnosine cytotoxicity occurred, at least in
part, via AKT inhibition in KRAS-mutated cells. The efficacy of
SC-79 at inducing P-AKT was verified by western blotting
(Figure S5B).
We next tested carnosine’s effect on the growth of subcutane-
ous SW48 KRASG12V and KRASWT xenografts in mice. Remark-(H) P-AKT induction was assessed upon GLO1 silencing using two siRNAs in CR
(I and J) The induction of P-AKT by MGO is reverted by carnosine (I) and amin
normalized for b-actin and are representative of at least three independent expe
See also Figure S3.ably, intraperitoneal injections of carnosine induced a significant
decrease in KRASG12V tumor growth but had no impact on
KRASWT cells (Figure 6H). MGO adducts, Hsp27, P-AKT, and
Ki67 IHC detection performed on experimental tumors showed
a consistent decrease in KRASG12V tumors treated with carno-
sine and brought their levels to those of KRASWT cells (Figures
6I). These in vivo data are in good complementarity with in vitro
observations, as they point to the particular reliance of KRASG12V
cells on MGO stress and demonstrate the anti-tumor efficacy of
carnosine against KRAS-mutated CRC tumors.
Carnosine Resensitizes KRAS-Mutated CRC Cells to
Cetuximab In Vitro and In Vivo
Our demonstration of the importance of MGO stress for
KRASG12V survival and tumor growth prompted us to test the
possibility that carnosine could resensitize KRAS-mutated
CRC cells when used in combination with cetuximab. As ex-
pected, cetuximab treatment of SW48 KRASG12V cells did not
induce a significant increase of their apoptotic rate (Figure 7A).
In comparison, carnosine tripled the proportion of apoptotic
cells. Moreover, co-treatment with cetuximab and carnosine
proved to be more efficient than each treatment considered
alone (Figure 7A). Thus, the shutdown of the AKT major survival
pathway using carnosine resensitized KRAS-mutated cells to
cetuximab. Enhanced apoptosis upon combined treatment
was further underlined by increased PARP cleavage and cas-
pase 3 (Figure 7B). To strengthen these important conclusions,
we next conducted in vivo experiments where we treated mice
bearing KRAS-mutated SW48 (Figure 7C), HCT116 (Figure 7D),
and LIM1215 (Figure 7E) tumors with both cetuximab and carno-
sine. Combined treatment showed a significant blockade of
tumor growth compared with separate cetuximab and carnosine
treatments. Altogether, these data support the rationale for
combining cetuximab with MGO scavenger molecules in the
mutant KRAS CRC genetic setting.
Induction of MGO Stress Renders Sensitive LIM1215
Cells Resistant to Cetuximab
Based on these results, we reasoned that the induction of MGO
stress in KRASWT LIM1215 cells that are sensitive to cetuximab
should induce P-AKT and ultimately decrease their sensitivity to
cetuximab. To test this hypothesis, we generated KRASWT
LIM1215 cells stably depleted for GLO1 using specific small
hairpin RNAs (shRNAs). In these cells, the induction of endoge-
nous MGO stress was evidenced by the detection of MGO
adducts (Figure 7F) and intracellular MGO level quantification us-
ingMBo probe (Figure 7G). MGO-stressed cells showed a signif-
icant induction of P-AKT (Figure 7H) and proved to be resistant to
cetuximab, as demonstrated by their respective growth curves
(Figure 7I) and cetuximab half-maximal inhibitory concentration
(IC50) calculation (Figure 7J). Collectively, these data indicate
that MGO stress induces AKT activation and confers resistance
to cetuximab in wild-type KRAS CRC cells. In fact, the MGOC cells. Efficient GLO1 silencing is shown.
oguanidine (J) after 3 h of co-treatment in CRC cells. All immunoblots were
riments.






Figure 5. The PI3K/mTORC2 Axis and MGO-Hsp27 Accumulation Contribute to MGO-Mediated AKT Activation in CRC Cells
(A) Western blot detection of P-PI3K and PI3K in CRC cells upon MGO treatment (3 h) at the indicated concentrations. b-Actin was used for normalization.
(B) Western blot detection of Rictor and mTOR in KRASWT CRC cells upon MGO treatment (3 h) at the indicated concentrations. Hsc70 was used for normal-
ization.
(C and D) Levels of P-AKT and AKT were assessed after 3-h co-treatment withMGO and torin 1 or rapamycin in SW48 (C) and LIM1215 (D) CRC cells. b-Actin was
used for normalization.
(E) IP of MGO-adducts in SW48 CRC cells using anti-argpyrimidine monoclonal antibody. Mouse immunoglobulin G (IgG) was used as control. Total cell lysates
(input) and IPs were immunoblotted (WB) using the indicated antibodies.
(legend continued on next page)
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stress condition recapitulates by itself the features of mutant
KRAS resistance to cetuximab and therefore could explain, at
least in part, the lack of efficacy of this drug in the majority of
advanced CRC patients with wild-type KRAS tumors.
DISCUSSION
Energetic metabolism adaptation is a characteristic feature of
cancer (Hanahan and Weinberg, 2011). Metabolic pathways
such as glycolysis are notably rewired in order to divert glucose
into anabolic pathways to satisfy the demand for cellular building
blocks (Vander Heiden et al., 2009). These last decades, the
study of oncometabolites such as MGO has attracted much in-
terest, as they point to cancer cell properties that could be ther-
apeutically exploited in different types of cancer (Sullivan et al.,
2016). Changes in the levels of specific metabolites have been
implicated in cancer initiation, progression, and drug resistance.
The reprogramming of tumor metabolism is notably under the
control of oncogenic signals. In particular, the RAS oncogene
has been shown to promote glycolysis (Racker et al., 1985;
Yun et al., 2009). MGO levels in cancer cells result from the bal-
ance between MGO formation, mainly as a by-product of glycol-
ysis, and its detoxification by the glyoxalase system (Bellahcène
et al., 2018). In this study, we demonstrate that mutant KRAS tu-
mors showed elevatedMGO adducts when compared with wild-
type KRAS CRC tumors. KRASG12V and KRASWT isogenic CRC
cell lines presented with similar GLO1 detoxification activity,
thus indicating that it is MGO production and adducts formation
that are favored in mutant-KRAS cells. Consistently, glucose
tracing experiments proved that the glycolytic flux is intensified
in mutant KRAS when compared with wild-type cells and that
glucose is the main source of MGO in CRC cells. The concept
defining cancer cell dependence on glycolysis to resist to tar-
geted therapy has been well documented in melanoma. Indeed,
BRAF inhibitors possess anti-glycolytic activity, and glucose
metabolism is restored upon development of acquired resis-
tance in melanoma (Hardeman et al., 2017; Parmenter et al.,
2014). Consistently, cetuximab proved to reverse the Warburg
effect in head and neck squamous cell carcinoma (HNSCC)
through HIF-1 alpha inhibition, and HNSCC cells with acquired
cetuximab resistance expressed high HIF-1 alpha levels and
were highly glycolytic (Lu et al., 2013).
We demonstrated that an important consequence of the MGO
stress condition in CRC cells is the activation of AKT signaling.
MGO consistently increased the phosphorylation of AKT, even
over a high basal level, in all CRC cell lines analyzed indepen-
dently of their mutational profile. AKT activation was reversed us-
ing MGO scavengers, thus establishing a direct link between
MGO oncometabolite and this key pro-survival signaling(F) Reverse IP using anti-Hsp27 allowed the detection of an ~27-kDa argpyrimid
(G) Parallel detection of MGO- Hsp27 and P-AKT in the indicated human CRC c
(H) Recombinant human Hsp27 (rhHsp27) or MGO-Hsp27 (MGO-rhHsp27) was
Methods. The effect of MGO-rhHsp27 on AKT activation is shown.
(I) Loss of MGO-mediated AKT activation in MGO-Hsp27-depleted cells using sp
(J and K) Detection of MGO-Hsp27 and P-AKT levels in SW48 KRASWT and KRAS
treatment. b-Actin was used for normalization. All western blots are representati
See also Figure S4.pathway in CRC. We have shown that KRASG12V cells rely on
the PI3K/AKT pathway for their survival and that experimental
tumors show significantly decreased growth inhibition in the
presence of carnosine. On the contrary, KRASWT tumors and
cells presented with low MGO stress and P-AKT and were less
dependent on AKT activity for their survival. Accordingly, they
proved to be insensitive to MGO stress blockade when xeno-
grafted in mice.
Approximately one-fourth of human CRC tumors harbor
mutations in both KRAS and PI3KCA (Parsons et al., 2005).
The selective advantage conferred by such apparently redundant
signalization has been notably associated with an aggravated
resistance to anti-EGFR therapy (Jhawer et al., 2008) and the
suppression of oncogene-induced senescence (Kennedy
et al., 2011). In the context of MGO stress, another
non-negligible benefit from AKT activation is its well-known role
as a driver of the Warburg effect. For example, AKT triggers
increased glucose uptake through the upregulation of glucose
transporters (Elstrom et al., 2004; Courtnay et al., 2015), resulting
in enhanced glycolytic flux, cell growth, and survival (Robey and
Hay, 2009). These observations let us propose a vicious cycle
where MGO stress triggers AKT activity that in turn sustains the
glycolytic flux, which then produces more MGO in cancer cells.
Cetuximab therapy is aimed at targeting the major pathways
activated through EGFR. Based on their screening of 22 CRC
cell lines for cetuximab response, Jhawer and collaborators
(Jhawer et al., 2008) concluded that the cell lines that acquire
constitutive activation of the PI3K/AKT pathway have a dimin-
ished dependence on canonical EGFR-ligand-induced signaling
and are more resistant to cetuximab. One important finding of
our study is that sensitive KRASWT cells that undergo MGO
stress switch to a dominant AKT dependence for their survival
and become resistant to cetuximab. Altogether, these results
not only point to pro-survival signals induced by MGO stress
contributing, at least in part, to cetuximab resistance in mutant
KRAS condition but also provide essential information for under-
standing the resistance to EGFR-targeted therapy reported in
wild-type KRAS clinical setting. In fact, up to 50% of patients
with wild-type KRAS tumors are resistant to cetuximab, and
the quest for predictive biomarkers and new therapeutic targets
is still the object of intense research (De Roock et al., 2011; Sal-
gado et al., 2018).We proposeMGO-mediated AKT activation as
an additional mechanism of resistance to cetuximab that does
not involve the well-described genetic alterations affecting
downstream and cross-talk effectors of EGFR signaling shown
to negatively affect sensitivity to EGFR inhibitors (De Roock
et al., 2010; Di Nicolantonio et al., 2008; Sartore-Bianchi et al.,
2009). It would be interesting to check whether MGO stress sta-
tus could predict, among quadruple wild-type CRC tumorsine adduct corresponding to MGO-Hsp27.
ells.
introduced into SW48 KRASWT cells with BioPORTER as described in STAR
ecific siRNAs directed against Hsp27.
G12V cells upon carnosine (100mM, 3 h) (J) and aminoguanidine (10 mM, 6 h) (K)
ve of at least three independent experiments.






Figure 6. Carnosine Specifically Inhibits KRASG12V Cell Survival through AKT Inhibition
(A) Determination of half-maximal inhibitory concentration (IC50) for LY294002, BYL719, and MK2206 in SW48 CRC cells as described in STAR Methods. Data
were analyzed using an unpaired Student’s t test and shown as mean values ± SEM of three independent experiments.
(B) Apoptosis analysis in CRC cells treated with LY294002 (50 mM, 8 h), BYL719 (40 mM, 24 h), andMK2206 (40 mM, 24 h). Annexin-V-positive cells were quantified
and shown as the percentage of apoptotic cells. All data are presented as mean values ± SEM of three independent experiments and were analyzed using two-
way ANOVA followed by Bonferroni’s test.
(legend continued on next page)
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(KRAS/NRAS/BRAF/PI3KCA), those that display MGO-induced
dependence on PI3K/AKT for their survival and will be refractory
to cetuximab treatment but sensitive to MGO blockade.
The accumulated evidence indicates that the mechanisms that
cause primary resistance can also be responsible of acquired
resistance to cetuximab (i.e., HER2 and MET amplifications and
genetic alterations of RAS/RAF/MEK) (Bray et al., 2019; Li et al.,
2019; Troiani et al., 2016; Van Emburgh et al., 2014). We cannot
exclude that MGO-mediated AKT activation occurring upon
glycolytic switch (triggered by KRAS mutation or other mecha-
nisms) could also play a role in acquired resistance to EGFR-
targeted therapies in CRC. Reliable preclinical models recently
validated such as xenospheroids generated from patient-derived
xenografts (Luraghi et al., 2018) will prove very useful to broaden
our understanding of the role of glycolysis-inducedMGO stress in
acquired resistance to anti-EGFR therapy in CRC.
Being a critical regulator of AKT activity, mTORC2 protein
kinase lately gained more attention as a key player in cancer
cell survival, energetic metabolism, and proliferation. We show
that MGO-stress-mediated AKT activation depends, at least in
part, on the induction of mTORC2 expression in CRC cells.
These findings provide with an unanticipated mechanism of
regulation of mTORC2, which receives inputs mainly from
growth factors and cytokines. Mechanistically, we also demon-
strated that endogenous and exogenous MGO stress induces
AKT activation that is lost upon Hsp27 silencing. AKT is a known
target for Hsp27 chaperone activity, which prevents its dephos-
phorylation and degradation, hence promoting its stability and
activation (Mearow et al., 2002). Hsp27 expression is increased
in a variety of malignancies, including gastric (Huang et al., 2010)
and pancreatic (Melle et al., 2007) cancers, and its overexpres-
sion is a bad prognostic factor in CRC (Han et al., 2018; Yu
et al., 2010). MGO modification of Hsp27 has been previously
shown to be essential to its repressing activity on caspase acti-
vation and cancer cell evasion from apoptosis (Oya-Ito et al.,
2011; Sakamoto et al., 2002; van Heijst et al., 2006). Our demon-
stration of high levels of stable MGO-Hsp27 in mutant KRAS
CRC cells appears to be of crucial importance in the context of(C) Representative pictures of the clonogenic assay performed in presence of in
STAR Methods, and numbers of colonies are presented as mean ± SEM of two
(D) Determination of IC50 for carnosine in SW48 CRC cells as described in STAR M
mean values ± SEM of three independent experiments.
(E) Apoptosis analysis in SW48 CRC cells treated with carnosine (100 mM, 48
quantified and shown as the percentage of apoptotic cells. All data are presented
using one-way ANOVA followed by Bonferroni’s test.
(F) Cleaved PARP and cleaved caspase-3 apoptosis markers in SW48 CRC cells
(G) Apoptosis analysis in SW48 KRASG12V CRC cells treated with carnosine (200
Annexin-V-positive cells were quantified and shown as the percentage of apop
relative to its corresponding control condition. All data are presented asmean valu
ANOVA followed by Bonferroni’s test.
(H) SW48 KRASWT and KRASG12V CRC cells were injected subcutaneously in the
intraperitoneal injection (100 mg/kg, 3 times/week). After 8 carnosine injections,
mean values ± SEM.
(I) Experimental tumors were subjected to IHC staining of MGO adducts, Hsp27,
vehicle-(NaCl)-treated experimental tumors are shown. Scale bar represents 100
(J) The proportion of experimental tumors presenting the indicated immunostainin
Ki67, as defined in STARMethods, is shown. Data were analyzed using one-way
Bonferroni’s tests were applied for simple or multiple comparisons, respectively
See also Figure S5.their resistance to anti-EGFR therapy. Taken collectively, these
studies and ours let us propose that the detection of global
MGO adducts levels or specific MGO stress adducts such as
MGO-Hsp27 could represent an interesting prediction tool to
help stratify patients likely to benefit from anti-EGFR therapy.
Given the difficulties associated with directly inhibiting the
KRAS oncoprotein, treating mutant KRAS CRC remains a major
challenge. EGFR signaling represents the main convergent
pathway that is intensively explored in preclinical studies and
clinical trials for a better understanding of anti-EGFR therapy
resistance in CRC. The complexity of the EGFR/MEK/ERK
signaling network involves numerous feedback loops and exten-
sive cross-talk nodes with other signaling pathways and
compensatory pathways, providing ample opportunities for cir-
cumventing the effects of MEK and PI3K/mTOR inhibitors used
alone or in combination with EGFR blockade. A recent excellent
review recapitulates the mechanisms of primary and secondary
resistance to anti-EGFR therapy and presents the numerous
related clinical trials and their conclusions (Parseghian et al.,
2019). In fact, most of the resistancemechanisms revealed aber-
rant reactivation of key intracellular signals that were basically
targeted by the drugs. For example, inhibition of AKT unexpect-
edly reactivated receptor tyrosine kinase signaling and expres-
sion, thereby inducing PI3K, ERK, and other crucial effectors
(Chandarlapaty et al., 2011). Several studies highlighted the
importance of PI3K/AKT pathway activation as an escapemech-
anism underlying acquired resistance in response to an MEK in-
hibitor (Turke et al., 2012) or combined cetuximab/MEK therapy
(Vitiello et al., 2019) in KRAS-mutated CRC cell lines.
One key finding of this study is the resensitization to cetuximab
of KRAS-mutated cells using MGO scavengers. Carnosine has
been previously shown to exert anti-proliferative effects against
cancer cells (Iovine et al., 2012; Lee et al., 2018), and oncolytic
adenoviruses loaded with carnosine showed anti-tumor activity
in vitro and in vivo (Garofalo et al., 2016). Until recently, the po-
tential therapeutic use of carnosine in human has been limited
by serum and tissue carnosinases. Carnosinol, a stable carno-
sine analog with high oral bioavailability and resistant tocreased concentrations of carnosine. Colonies were counted as described in
independent experiments.
ethods. Data were analyzed using unpaired Student’s t test and are shown as
h) and aminoguanidine (10 and 30 mM, 48 h). Annexin-V-positive cells were
as mean values ± SEM of three independent experiments and were analyzed
in parallel experiment as in E.
mM, 24 h) and pretreated with SC79 at the indicated concentrations for 2 h.
totic cells. Each fold change of percentage of apoptotic cells was quantified
es ± SEM of three independent experiments and were analyzed using one-way
flank of NOD-SCID mice (20 mice/group). Mice were treated with carnosine by
mice were sacrificed and primary tumors were collected. Data are shown as
P-AKT, and Ki67 proliferation marker. Representative pictures of carnosine- or
mm.
g scores (low and high) for MGO adducts, Hsp27, P-AKT, and proliferation rate
or two-way ANOVA depending on the number of grouping factors. Dunnett’s or
. ***p < 0.001, **p < 0.01, and *p < 0.05; ns, not significant.
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LIM1215  KRASWT 
Figure 7. Carnosine Resensitizes KRAS-Mutated CRCCells to Cetuximab, and the Induction of MGOStress Is Sufficient to Render LIM1215-
Sensitive Cells Resistant to Cetuximab
(A) Apoptosis analysis of CRC cells treated with cetuximab (30 mg/mL, 48 h) in the presence of carnosine (100mM, 48 h). Annexin-V-positive cells were quantified,
and data are presented as mean values ± SEM of three independent experiments. One-way ANOVA was performed followed by Bonferroni’s test.
(B) Cleaved PARP and cleaved caspase-3 were assessed in KRASG12V cells in the same conditions as in A.
(C–E) SW48KRASG12V (C), HCT116 KRASG13D (D), and LIM1215 KRASG12V (E) CRC cells were injected subcutaneously in the flank of NOD-SCIDmice (6–10mice/
group). Mice were treated with carnosine (100 mg/kg, 3 times/week) and/or cetuximab (0.5 mg/treatment, 2 times/week). Mice were sacrificed, and tumors were
collected. All data are shown as mean values ± SEM and were analyzed using two-way ANOVA.
(legend continued on next page)
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carnosinases, has been recently developed and proposed to
treat obesity-related metabolic disorders (Anderson et al.,
2018). Considerable attention has been given to the use of natu-
ral substances as anticancer drugs. This is even more crucial
when proposing combination therapeutic strategies to achieve
efficacy against resistant tumors and to observe meaningful
clinical benefit. Indeed, the emergence of doublet or triplet com-
binations tested clinically to overcome acquired resistance to
cetuximab will expectedly have additional toxicities for the
patients.We propose that stable carnosine analogs, such as car-
nosinol, administered in combination with cetuximab could be
not only an effective but also a safe anti-tumor therapy. Future
studies are needed to strengthen the rationale for combining
anti-EGFR therapy with MGO scavengers to treat resistant
glycolytic tumors harboring or not oncogenic RAS mutations.
In sum, our data underscore the importance of taking into ac-
count energeticmetabolic dysregulation next to tumor genotyping
when stratifying CRC patients prior to EGFR-targeted therapy.
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Biobank) and Pr. A-F. Donneau (Department of Public Health, University of
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Liège, Belgium). This work was supported by a grant from Télévie-FNRS
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Argpyrimidine (Oya et al., 1999) Cat# mAb6B
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Glyoxalase 1 BioMAC Cat# 02-14
MG-Hs (3D11) Cell Biolabs Cat# STA-011
P-AKT Cell Signaling Cat# 4060; RRID: AB_2315049
AKT Cell Signaling Cat# 9272; RRID: AB_329827
P-PI3K Cell Signaling Cat# 4228; RRID: AB_659940
PI3K Cell Signaling Cat# 4257
GLUT1 Cell Signaling Cat# 12939; RRID: AB_2687899
P-PDH Abcam Cat# 92696; RRID: AB_10711672
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P-PKM2 Cell Signaling Cat# 3827; RRID: AB_1950369
PKM2 Cell signaling Cat# 4053; RRID: AB_1904096
P-P70S6K Cell signaling Cat# 2708; RRID: AB_390722
P-GSK3beta Cell signaling Cat# 9331; RRID: AB_329830
GSK3beta BD Biosciences Cat# 610202; RRID: AB_397601
Hsp27 Enzo Life Sciences Cat# ADI-SPA-803-D; RRID: AB_10615084
Cleaved caspase 3 Cell Signaling Cat# 9664; RRID: AB_2070042
Cleaved PARP Cell Signaling Cat# 5625; RRID: AB_10699459
HKII Cell Signaling Cat# 2867; RRID: AB_2232946
PFKFB3 Cell Signaling Cat# 13123; RRID: AB_2617178
Rictor Cell Signaling Cat# 2114; RRID: AB_2179963
mTOR Cell Signaling Cat# 2983; RRID: AB_2105622
Hsc70 Santa Cruz Cat# Sc-7298; RRID: AB_627761
Bacterial and Virus Strains
pSPAX2 Addgene #12260
VSV-G encoding vector Emi et al., 1991 N/A
GLO1#1 shRNA plasmid Sigma-Aldrich TRCN0000118627
GLO1#4 shRNA plasmid Sigma-Aldrich TRCN0000118631
Non-target shRNA plasmid Sigma-Aldrich SHC005
Chemicals, Peptides, and Recombinant Proteins
L-carnosine Sigma-Aldrich Cat# C-9625
Aminoguanidine Sigma-Aldrich Cat# 396494
Deoxyglucose Sigma-Aldrich Cat# D-8375
Methylglyoxal Sigma-Aldrich Cat# M-0252
Cycloheximide Sigma-Aldrich Cat# C-7698
Human recombinant Hsp27 Enzo Life Sciences Cat# ADI-SPP-715-D
Torin 1 Selleckchem Cat# S2827
SC79 Selleckchem Cat# S7863
LY294002 Selleckchem Cat# S1105
BYL719 Selleckchem Cat# S2814
MK2206 Selleckchem Cat# S1078
Rapamycin Calbiochem Cat# 553210
Cetuximab Merck C225
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NAD+ Sigma-Aldrich Cat# N7004
D-Lactate Dehydrogenase Sigma-Aldrich Cat# L3888
Glutathione reduced (GSH) Sigma-Aldrich Cat# G4251
Bisbenzimide Sigma-Aldrich Cat# 33258
Seahorse XF Base Medium Agilent Cat# 102353-100
Oligomycin Sigma-Aldrich Cat# O4876
Lipofectamine 2000 Thermo Fisher Cat# 11668-019
Methyl diaminobenzene-BODIPY (MBo) Wang et al., 2013 N/A
Critical Commercial Assays
Pierce BCA Protein Assay Kit Pierce Cat# PI-23225
Vectastain ABC Kit Vector Laboratories Cat# PK-6100
FITC-Annexin V apoptosis Detection Kit I BD Biosciences Cat# 556547
BioPORTER Protein Delivery Kit Sigma-Aldrich Cat# BPQ24
qPCR Lentivirus Titration Kit ABM Cat# LV900
Experimental Models: Cell Lines
Isogenic SW48 (KRASWT) Horizon Discovery Cat# HD PAR-006
Isogenic SW48 (KRASG12V) Horizon Discovery Cat#: HD 103-007
Isogenic LIM1215 (KRASWT) Horizon Discovery Cat# HD PAR-108
Isogenic LIM1215 (KRASG12V) Horizon Discovery Cat# HD 116-006
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GraphPad Prism 6 Graphpad Software N/A
Fiji-ImageJ https://imagej.net/Fiji N/A
IncuCyte S3 (V2019A) Essen Bioscience N/ALEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Akeila
Bellahcène (a.bellahcene@uliege.be). This study did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Clinical tumor samples
Retrospective series of CRC samples comprising colon and rectum primary tumors were provided by the Biobank of the University
Hospital of Liège (Liège University, Belgium). The use of human sample collections has been approved by the institutional ethics
committee of the University of Liège (ethics committee approval number 2013/302). The cohort of 48 colon cancer patients consisted
of 22males and 26 females diagnosed between October 2006 and January 2018. Themedian age was 66 years (range: 33–86 years).
Sex, age, pTNM staging and grade were retrieved from medical reports (Table S1). KRAS, NRAS, BRAF, PTEN and PIK3CA
mutational status of CRC tumors was assessed as described below and summarized in Table S1. The cohort of 84 rectum cancere2 Cell Reports 30, 1400–1416.e1–e6, February 4, 2020
patients consisted of 51 males and 33 females diagnosed between September 2009 and December 2015. The median age was
68 years (range: 39–92 years). Sex, age, pTNM staging and grade were retrieved from medical reports and presented in Table S2.
For TNM prognostic stage determination, we referred to the 7th edition of the AJCC-UICC (the American Joint Committee on Cancer
and Union Internationale Contre le Cancer) that also includes grade.
Cell lines
Isogenic human CRC cell lines SW48 and LIM1215 were purchased from Horizon Discovery. The clones used were heterozygous
knock-in (G12V/+) of KRAS activating mutation KRASG12V (SW48 cat. no. HD 103-007 lot 00053 and LIM1215 cat. no. HD 116-006
lot 2874) and homozygous wild-type KRAS expressing cells (SW48 cat. no. HD PAR-006 lot 11916 and LIM1215 cat. no. HD PAR-
108 lot 2706). SW48 isogenic cell lines were cultured in RPMI medium (Lonza) containing 10% fetal bovine serum (FBS, ThermoFisher
Scientific) and 4.5 g/L of glucose. LIM1215 isogenic cell lines were cultivated in RPMI medium (Lonza) containing 10% fetal bovine
serum (FBS, ThermoFisher Scientific), insulin (1 mg/mL), hydrocortisone (1 mg/mL) and 1 g/L of glucose. SW480, Lovo, HCT116,
LS174, HT29 humanCRC cell lines, all purchased fromAmerican TypeCultureCollection (ATCC), were cultured inDMEMmediumcon-
taining 10%FBS and 4.5 g/L of glucose. All cell lines were authenticated by STR profiling at Leibniz-Institute DSMZ (Braunschweig) and
were regularly checked for mycoplasma contamination using MycoAlert mycoplasma detection kit (Lonza).
Mouse xenografts
All animal experimental procedureswere performed according to the Federation of European Laboratory Animal Sciences Associations
(FELASA) andwere reviewedand approvedby the Institutional AnimalCare andEthicsCommittee of theUniversity of Liege (ethics com-
mittee approval number 17-1913). Animals were housed in theGIGA-accredited animal facility (University of Liege) under standard con-
ditions (12 hr light/dark cycle, light on at 7 a.m., food and water provided ad libitum). SW48 KRASWT and KRASG12V cells and HCT116
(33 106 cells/mouse) were suspended in FBS-free culture medium. LIM1215 KRASG12V cells (2,53 106 cells/mouse) were suspended
in FBS-free culture medium with matrigel (1:1 ratio). Cell suspensions were injected subcutaneously into the right posterior flanks of 7-
week-old immunodeficient NOD-SCIDmalemice (number ofmice/group is as indicated in figure legend). Tumor volumewasmonitored
three times per week using caliper and was calculated by the modified ellipsoidal formula (tumor volume = 1/2 (length3width2). When
tumors reached a volume of approximately 0.2 cm3, mice received intra-peritoneal injections of carnosine and/or cetuximab. Mice
received carnosine three times per week (100 mg/kg/injection) and/or cetuximab twice a week (0.5 mg/injection). After 7-8 carnosine
injections, mice were euthanized and tumors were collected. Tumors were fixed and embedded in paraffin for immunohistochemistry.
METHOD DETAILS
Mutational status analysis using NGS
DNA was extracted from FFPE human CRC tumor samples. The regions of interest and detailed below were amplified using a lab-
oratory developed multiplex PCR using QIAGEN multiplex PCR plus kit (QIAGEN). Molecular barcoding was performed with ‘drMID
DX 1-48 for Illumina NGS system‘ or ‘drMID DX 49-96 for Illumina NGS system‘ (Agilent, USA) according to the manufacturer’s pro-
tocol. PCR products obtained from each sample were pooled and purified using Agencourt AMPure XP beads (Beckman Coulter,
USA). Each patient library was then quantified using Quanti-it Picogreen dsDNA Assay Kit (Fisher Scientific, USA) and the Fluostar
Optima System (BMG Labtech, Germany). Equimolar amounts of each patient PCR products were pooled to obtain the final library.
The library was then quantified and denatured according to the standard Illumina’s MiSeq protocol. Sequencing was performed with
aMiSeq v3 cartridge with 500 cycles (Illumina, USA). Alignment of the fastq files and variant calling weremade using SeqNext Version
4.1.1 build 511 (JSI medical systems, Germany). Regions of interest: KRAS [exons 2, 3 and 4 (full)], NRAS [exons 2, 3 and 4 (full)],
BRAF [exons 11 and 15 (full)],PIK3CA [hotspots in exon 9 and 20 (codons 542, 545 and 1047 covered)] andPTEN [exons 5 and 7 (full)].
Immunohistochemistry (IHC)
Formalin-fixed paraffin embedded sections were deparaffinized in xylene and rehydrated. Sections were treated with 3% hydrogen
peroxide in methanol for 30 min to block endogenous peroxidase activity and washed in PBS for 20 min. Antigen retrieval was
performed in sodium citrate buffer (10 mM) pH 6 at 95C for 40 min. To block non-specific serum-binding sites, sections were
then incubated with 1.5% normal serum (Vector Laboratories) for 30 min. Next, they were incubated with mouse anti-Argpyrimidine
(mAb6B, 1:5000), rabbit anti-Hsp27 (Enzo Life Sciences, 1:100 dilution) rabbit anti-P-AKT (Cell signaling, 1:100 dilution) and mouse
anti-Ki67 (Dako, 1:100 dilution) antibodies overnight at 4C. Antibody binding was detected using anti-mouse or anti-rabbit
biotinylated secondary antibody (Vector Laboratories) for 30 min at room temperature. Sections were then incubated with the
avidin-biotin-peroxidase complex (Vectastain ABCKit) for 30min followed by immunoreactivity revelation with 3,30 diaminobenzidine
tetrachloride. Slides were finally counterstained with hematoxylin, dehydrated and mounted with DPX (Sigma-Aldrich). Tissue sec-
tions incubated without primary antibody showed no detectable immunoreactivity.
Seahorse analysis
Extracellular acidification rate (ECAR) of cells was determined using Seahorse XFp extracellular flux analyzer (Agilent) according to
manufacturer’s recommendations and as we described previously (Nokin et al., 2017; Rademaker et al., 2018). SW48 and LIM1215Cell Reports 30, 1400–1416.e1–e6, February 4, 2020 e3
cells were seeded (30,000 cells/well) in XFp mini-plates (Agilent) and allowed to attach overnight. Cells were kept at 37C for 1 hr in
unbuffered serum-free DMEM (Basal DMEM, Agilent) containing glutamine (2 mM), pH 7.4 before the measurements. During the
assay, cells were successively stressed with glucose (20 mM), oligomycin (1 mM) and 2-deoxyglucose (50 mM). All results were
normalized according to the cell number evaluated by Hoechst (2 mg/mL) incorporation after cold methanol/acetone fixation. Repre-
sentative results of at least two independent experiments are shown.
Metabolomics
Extraction of polar metabolites was performed after 48 hours of cell culture (steady state). For tracing experiments, cells were further
incubated in glucose-free RPMI (GIBCO, Thermo Fisher Scientific) supplemented with 10% FBS and 10 mM 13C-glucose (CLM-
1396,Cambridge IsotopesLaboratories).Briefly, cellswerewashedwith ice-coldPBSandquickly incubated in ice-coldextractionbuffer
(50%Methanol - 30%Acetonitrile - 20%H2O) for 5minutesunder agitation.Supernatantwas collected,mixed for 10minutes andcentri-
fuged at 16.000 x g to remove cell debris. All the steps were performed at 4C. Finally, supernatant was transferred to glass HPLC vials
(Thermo Fisher Scientific) and analyzed aspreviously described (Mackay et al., 2015; Rath et al., 2018) using aQExactiveOrbitrapmass
spectrometer (ThermoFisherScientific) coupledwith a ThermoUltimate3000HPLCsystem. TheHPLCsetup consisted of a ZIC-pHILIC
column (SeQuant, 15032.1mm,5mm,MerckKGaA,Darmstadt,Germany),withaZIC-pHILICguardcolumn (SeQuant, 2032.1mm)and
an initialmobile phaseof 20%20mMammoniumcarbonate, pH9.2, and80%acetonitrile. 5ml of sampleswere injectedandmetabolites
were separated over a 15minute mobile phase gradient, decreasing the acetonitrile content to 20%, at a flow rate of 200 mL/min and a
column temperature of 45C. The total analysis timewas 25minutes. Allmetaboliteswere detected across amass range of 75-1000m/z
using theQExactivemass spectrometer at a resolution of 35,000 (at 200m/z), with electrospray (ESI) ionisation and polarity switching to
enablebothpositive and negative ions tobedetermined in the same run. Lockmasseswereusedand themassaccuracyobtained for all
metabolites was below 5ppm. Data were acquired with Thermo Xcalibur software. Metabolites identification was performed using
ThermoTraceFinder 4.0 software (ThermoFisher Scientific). Commercial standards of allmetabolites detected havebeenanalyzedpre-
viously on this LC-MS system with the pHILIC column. Peak areas for each metabolite were normalized to protein content.
MGO measurement
Cells were either treated with carnosine (100 mM, 48 hr), aminoguanidine (10 mM, 48 hr) or with siRNA directed against GLO1. Forty-
eight hours culture media were collected and centrifuged. Supernatants were snap-frozen and kept at80C until analysis. Levels of
MGOwere determined in conditioned medium by derivatization with o-phenylenediamine (oPD) and analyzed by stable isotope dilu-
tion ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) as described previously (Scheijen and
Schalkwijk, 2014). Briefly, 30 ml of culture medium were mixed with 90 mL oPD (10 mg oPD in 10 mL of 1.6 mol/l perchloric acid)
in an Eppendorf cup. After an overnight reaction at room temperature and shielded from light, 10 mL of internal standard solution
was added. Samples were mixed and subsequently centrifuged for 20 min at 21,000 g at a temperature of 4C; 10 mL were injected
for UPLC/MS/MS analysis. MGO concentrations were normalized to the corresponding cell numbers. Data are presented as mean ±
SEM of three biological replicates.
For MGO tracing, cells were incubated with 13C-glucose (CLM-1396, Cambridge Isotopes Laboratories) for 48 hours. Both unlabeled
MGO and labeled MGO were derivatized and processed for LC/MS/MS on cell pellets and conditioned media of SW48 and LIM1215
cells as described above. Data are presented as chromatograms of one representative measure from 3 biological replicates.
Cellular MGO quantification
Methyl diaminobenzene-BODIPY (MBo) was used to detect endogenous MGO as we described previously (Nokin et al., 2016). Cells
were treated with 5 mMMBo in completemedium. After 1 hr, cells were washedwith PBS and incubated during 3 hr in the presence of
the indicated concentrations of MGO or 48 hr after GLO1 silencing using siRNAs. The presence of significant formaldehyde contam-
ination (< 3%) in methylglyoxal was excluded (lot: BCBQ9416V) by NMR analysis. Cells were trypsinized and analyzed by flow
cytometry (BD Biosciences FACSCalibur). Data are presented as mean ± SEM of three biological replicates.
Western blot analysis
Cell and tissue proteins were extracted in SDS 1% buffer containing protease and phosphatase inhibitors (Roche). Protein concen-
trations were determined using the bicinchoninic acid (BCA) assay (Pierce). Twenty mg of proteins were separated by 7.5 to 12.5%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane. Membranes were
blocked in TBS-Tween 0.1% containing 5% non fat dried milk (Bio-Rad) and were incubated overnight at 4C with the indicated
primary antibodies and listed in the Key Resources Table. Membranes were exposed to appropriate horseradish peroxidase-
conjugated secondary antibody anti-mouse (Dako, 1:3000 dilution) or anti-rabbit (Invitrogen, 1:3000 dilution) at RT for 1 hr. The immu-
noreactive bands were visualized using Enhanced Chemiluminescence Western Blotting substrate (Pierce). Immunoblots were
quantified by densitometric analysis and normalized for b-actin or Hsc70 using ImageJ software (Schneider et al., 2012).
D-lactate dosage
D-lactate concentrations were assessed in 48 hr cell culture media as described previously (Nokin et al., 2017). Briefly, conditionedme-
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was determined by comparing NADH formationmeasured at 320 nm to the absorbance of a calibration curve. D-lactate concentrations
were normalized per million cells and presented as mean ± SEM of three biological replicates.
GLO1 activity
GLO1 activity was assessed as described previously (Nokin et al., 2017). Briefly, proteins were extracted with RIPA buffer, quantified
andmixed with a pre-incubated (15min at 25C) equimolar (1 mM) mixture of MGO andGSH (Sigma-Aldrich) in 50mM sodium phos-
phate buffer, pH 6.8. S-D-lactoylglutathione formation was followed spectrophotometrically by the increase of absorbance at
240 nm. GLO1 activity is expressed as arbitrary units (A.U.) of enzyme per mg of proteins. Data are presented as mean ± SEM of
three biological replicates.
Determination of half-maximal inhibitory concentrations 50 (IC50)
Cells were plated in 24-well plate and treated for 24 hr with increasing concentrations of LY294002 (1 to 150 mM), BYL719 (1 to
100 mM), MK2206 (1 to 50 mM) or carnosine (1 to 500 mM). Cells were then washed, lysed by sonication and their DNA content
was assessed spectrophotometrically using bisbenzimide (Sigma-Aldrich) incorporation. IC50 values represent the concentration
of drug able to decrease by half the quantity of DNA.
Apoptosis assay
Apoptosis was assessed by using FITC-Annexin V apoptosis Detection Kit I (BD Biosciences) according to manufacturer’s instruc-
tions. Flow cytometry data were acquired on a FACSCalibur II and data were analyzed using CellQuest software (BD Biosciences).
Data are presented as mean ± SEM of at least three biological replicates.
Immunoprecipitation
Proteins were extracted in Tris-HCl pH 8 (20 mM), NaCl (137 mM), NP-40 1%, EDTA (2 mM) in presence of protease inhibitors and
were incubated under rotation at 4C during 30 min. Cell lysates were centrifuged at 14,000 g for 15 min at 4C. Five hundred mg of
proteins were incubated overnight with 5 mg of anti-argpyrimidine (mAb6B), 5 mg of anti-Hsp27 (Enzo Life Sciences) or the corre-
sponding control anti-mouse and anti-rabbit IgG (Zymed Laboratories) antibodies as indicated. The mixtures were then incubated
during 2 hr with protein G magnetic beads at 4C. After several washes, proteins were eluted and analyzed by western blot. Repre-
sentative western blots of three independent immunoprecipitation experiments are shown.
BioPORTER assay
Recombinant human Hsp27 (rhHsp27) was modified with MGO (500 mM) in PBS (100 mM) pH 7.4 at 37C during 24 hr. Native
rhHsp27 or MGO-modified rhHsp27 (MGO-rhHsp27) were incubated in presence of BioPORTER reagent according to the manufac-
turer’s instructions (Sigma-Aldrich). Briefly, 75 ml of PBS containing 7.5 mg of rhHsp27 or MGO-rhHsp27 were added to hydrate one
QuikEase tube containing the dried BioPORTER reagent. The mixture was gently incubated at room temperature during 5 min. Final
volume of the mixture was next brought to 500 mL with serum-free medium. After washing cells with serum-free medium, Bio-
PORTER/protein mix was transferred onto cells for 2 hr at 37C.
siRNA and shRNA transfections
Lipofectamine-mediated transfection was performed using 20 nM of each small interfering RNA (siRNA) as we described previ-
ously (Nokin et al., 2016). Lentiviral vectors (rLV) were generated at the GIGA Viral Vectors platform (University of Liege). Briefly,
Lenti-X 293T cells (Clontech, Montain View, CA, USA) were co-transfected with a pSPAX2 (Addgene plasmid #12260) and a VSV-
G encoding vector (Emi et al., 1991) along with shRNAs transfer lentiviral plasmids. Forty-eight, 72 and 96 hr post-transfection,
viral supernatants were collected, filtrated and concentrated 100x by ultracentrifugation. The lentiviral vectors were then titrated
with qPCR Lentivirus Titration Kit (ABM, Richmond, Canada). LIM1215 cells were stably transduced with shGLO1#1, shGLO1#4
and shNT and selected with puromycin (0.5 mg/ml, Sigma-Aldrich). siRNAs and shRNAs sequences are given in the Key
Resources Table.
Protein stability
Cells were seeded in 6-well plates overnight and changed to fresh medium supplemented with 10 mg/ml cycloheximide. Cell lysates
were prepared after culturing cells for the indicated lengths of time and total Hsp27, MGO-Hsp27, P-AKT, AKT and b-actin protein
levels were assessed using immunobloting as described above. A representative western blot of three independent experiments is
shown. Data were analyzed by nonlinear regression, and protein half-life was determined from first-order decay constants (k)
obtained using PRISM software program (GraphPad).
Clonogenic assay
Cells were seeded (2,000 cells/well) in 6 well-plates and allowed to attach overnight. Cells were kept in the same culture medium and
treated once at the indicated concentrations of carnosine. Fourteen days after cell plating, the cells were stained with 0.5% crystal
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were considered as colonies and counted using ImageJ software (Schneider et al., 2012). Data are presented as mean ± SEM of two
independent experiments.
Real-time proliferation assay
GLO1 stably depleted LIM1215 cells were seeded in triplicate into 96-well plate (20,000 cells/well). After overnight incubation, cells
were treated with increasing concentrations of cetuximab (0-1500 mg/ml) and the plate was inserted into the IncuCyte S3 Live-Cell
Analysis System for real-time imaging. Phase-contrast images were automatically acquired using a 10x objective lens (four images
per well) at 4 hr intervals during 72 hr. The IncuCyte Analyzer provides real-time cellular confluence data based on segmentation of
high-definition phase–contrast images. Cell proliferation is expressed as an increase in percentage of confluence relative to the
confluence quantified at the initial time of the experiment (4 hr). Cetuximab IC50 valueswere calculated based on IncuCyte confluency
data and represent the concentrations leading to a 50% decrease of relative confluency after 24 hr of treatment. IncuCyte assays
were performed on 3 biological replicates.
QUANTIFICATION AND STATISTICAL ANALYSIS
Evaluation of immunohistochemical staining
The immunostainingwas assessed and scored by two independent examiners. The scoring of argpyrimidines, Hsp27 and P-AKTwas
assessed according to the intensity of the staining as 0+ (negative) 1+ (low), 2+ (medium) and 3+ (high) and the extension of the stain-
ing as 0+ (negative), 1+ (10%–33%), 2+ (34%–66%) and 3+ (67%–100%). When the tumors showed some heterogeneity in the in-
tensity of the staining, the scoring of the staining intensity was assessed according to the staining of the most positive tumor cells,
when their estimated percentage represented at least 30% of the total positive tumor cell area. The results obtained with the two
scales were multiplied together, yielding a single scale with steps of 0, 1+, 2+, 3+, 4+, 6+, and 9+ (Waltregny et al., 1998). Final
IHC scores are shown as low (0+, 1+, 2+ and 3+) and high (4+, 6 and 9+). Ki67 immunostaining was evaluated as the percentage
of positive nuclei present in the whole sections as we described previously (Nokin et al., 2017). Low proliferative rate corresponds
to tumors presenting % 30% of positive nuclei and high proliferative rate to tumors presenting > 30% of positive nuclei.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Graphpad software, San Diego, CA). Technical and biological replicates
were performed as detailed in figure legends and material and methods sections. Results were reported as mean with standard de-
viation (SD) or standard error of mean (SEM) as indicated in figure legends. Two group comparisons were performed using unpaired
Student’s t test with or without Welch’s correction according to homoscedasticity. When an experiment required comparisons be-
tween more than two groups, we performed one-way or two-way ANOVA depending on the number of grouping factors. Dunnet’s or
Bonferroni’s test were applied for simple or multiple comparisons, respectively. In all cases, a bilateral p < 0.05 was considered as
statistically significant with a 95% confidence interval.
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